RxDoctor Payments Data

Gabriel Elia Jacusiel, MD

Nephrology · Lansing, MINPI 1528107547

Payments from drug & device makers

$4,297in general payments, 2019–2025

Across 194 payments — averaging $22.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$467
  • AstraZeneca$451
  • Calliditas Therapeutics US Inc.$317
  • Novartis$285
  • Bayer$284
  • Akebia Therapeutics Inc$272
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$3,94692%
  • Education$3518%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,297 in reported general payments places this provider in the 70th percentile of 325 nephrology providers in Michigan.

See all nephrology providers in Michigan

Medicare billing

Part B allowed, 2024
$186,334
Medicare patients
324
Services billed
1,402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol56$89,505
VelphoroSucroferric Oxyhydroxide16$51,579
AuryxiaFerric Citrate26$45,197
JardianceEmpagliflozin30$38,504
OzempicSemaglutide13$11,839
Sevelamer Carbonate46$8,071
Potassium Citrate ErPotassium Citrate35$4,867
Midodrine Hcl25$3,864
Cinacalcet Hcl19$3,562
Clonidine12$3,421
Hydralazine Hcl61$1,671
Losartan Potassium135$1,652
Calcitriol48$1,449
Lisinopril132$1,327
Sodium Polystyrene Sulfonate12$1,294

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$451$89,50556 claims
Fresenius USA Marketing, Inc.Velphoro$113$51,57916 claims
Akebia Therapeutics IncAuryxia$272$45,19726 claims
Boehringer IngelheimJardiance$148$38,50430 claims
Novo NordiskOzempic$69$11,83913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 325 nephrology providers in Michigan.

Other nephrology in Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →